Lilly To Cap Insulin Cost During Coronavirus

INDIANAPOLIS–Executives at the pharmaceutical company Eli Lilly say they are capping the out-of-pocket cost of insulin to help diabetics during the coronavirus.

They are introducing the Eli Lilly Insulin Value Program, which allows anyone with commercial insurance and those without insurance at all to fill their monthly prescription of Lilly insulin for $35.

“It’s critical that people with diabetes can reliably access insulin at a low, consistent out-of-pocket cost. Enabling a $35 per month insulin co-pay regardless of employment status will help many Americans in this difficult time,” said CEOs Aaron Kowalski and Thom Scher on behalf of the JDRF-Beyond Type 1 Alliance.

The program is now in effect and covers most Lilly insulins including all Humalog (insulin lispro injection 100 units/ML) formulations.

However, patients with government insurance such as Medicaid, Medicare, Medicare Part D or any State Patient or Pharmaceutical Assistance Program are not eligible for it.

A separate co-pay card for Humulin® R U-500 (insulin human injection, 500 units/mL) allows for a monthly prescription fill for as little as $25 for people with commercial insurance and can be accessed at Humulin.com.

“The Lilly Insulin Value Program is meant to help address the needs of people in this crisis, but we also remain committed to exploring additional solutions that provide meaningful impact for those living with diabetes beyond the current crisis,” said Mike Mason, President of Lilly Diabetes.

If you have any questions, you should call the Lilly Diabetes Solution Center at 833-808-1234. The Solution Center is open from 8 am to 8 pm Monday through Friday.

Eli Lilly is headquartered in Indianapolis.